The agreement from multiple state attorneys general, including those who had most aggressively opposed Purdue’s original settlement proposal, was disclosed late Wednesday.
Cancer-fighting nuclear medicine finding home in central Indiana
Indianapolis’ newest publicly company, Point Biopharma Inc., is the latest player in a field expected to see explosive growth as doctors and researchers look for new ways to shrink tumors.Read More
New Riley Children’s Health leader has big job, towering presence
Gil Peri, a 6-foot, 8-1/2-inch, gregarious administrator with an easy laugh, started his job on June 28, after spending about four years as president and chief operating officer at Connecticut Children’s Medical Center.Read More
Cybercriminals target internet-connected medical devices
Indiana University Health has created a lab to testing the vulnerability of hundreds or even thousands of devices, to protect both patients and the hospital system’s records.Read More
Indiana’s COVID vaccine rollout gets mixed reviews
While the state’s rollout of eligibility for the vaccine has come under some fire, many Hoosiers have begun planning for a summer and fall free from worry, ready to resume their normal lives.Read More
Mathilde Merlet oversees one of Eli Lilly and Co.’s fastest-growing products, a medicine called Taltz that treats a variety of dermatology and rheumatology disorders.
The announcement comes five months after the company introduced its new product Halo, which uses artificial intelligence to make recommendations related to the quality of medical devices.
With the help of a $2.3 million grant, Purdue University animal science professor Shihuan Kuang’s research will continue in an effort to better understand the origin and function of these newly-discovered stem cells.
The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.
Neuro Vigor says it will use $100,000 in early commercialization funds to “identify and validate” its lead drug candidate for the treatment of neuropathic pain in spinal cord injuries.
Emerging from the pandemic, health and life sciences companies have a unique opportunity to leverage lessons learned for the benefit of the patients they serve.
Matthew Sause took the helm of the 4,500-person Roche Diagnostics’ North American operations in Indianapolis in November 2019—just four months before the World Health Organization declared a pandemic and much of the planet went into lockdown.
This is a partial transcript of IBJ’s annual Life Sciences Power Panel, which took place virtually on April 30 with four of Indy’s biosciences leaders: 16 Tech CEO Bob Coy, GenePace Laboratories founder Sanjay Malkani, Elanco Animal Health CEO Jeff Simmons and Indiana University School of Medicine geneticist Tatiana Foroud.
Speakers at the IBJ Life Sciences Power Panel on Friday said their organizations have largely weathered the lockdown—raising records funds, taking on huge expansions, hiring new employees and reporting higher productivity.
Health care practitioners and insurers are fighting over the hefty prices hospitals charge for specialty drugs to treat patients with cancer, vision loss, low white-blood-cell count and other serious diseases.
Eli Lilly and Co. told Reuters news agency that it is working closely with the FDA to address concerns about the factory in Branchburg, New Jersey, which makes Trulicity.
Julie Cranfill lost her father to COVID-19 last March. Because of pandemic restrictions, she felt there was no way to publicly remember her dad, to tell the world what a wonderful father he was.
Former JW Marriott employee Lisette Woloszyk watched things go from bad to worse in March, as cancellations for the city’s hotels racked up alongside COVID-19 cases.